As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
-
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
-
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
-
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
-
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
-
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
-
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
-
REGULATORY CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
-
BUSINESS AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
-
REGULATORY Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
-
REGULATORY MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
-
REGULATORY CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
-
ORGANIZATION Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
-
REGULATORY DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
-
ORGANIZATION MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
-
REGULATORY Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
-
BUSINESS 25 Leading Drug Makers Report Overall Decline in Sales, Profits in 1st Half
November 24, 2011
-
ACADEMIA JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
-
BUSINESS Sanofi, Nichi-Iko to Copromote Latter's Generic Drugs
November 22, 2011
-
BUSINESS Sawai, Nichi-Iko Boost Inventory Ahead of Expected PAL Amendment
November 21, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…